Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Sierra Oncology

Sierra Oncology

Sierra Oncology is clinical stage drug development company, advancing targeted therapies for treating cancer patients.

Sierra Oncology is a publicly traded, clinical stage drug development company based in Vancouver, British Colombia. It is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.

The company's lead product candidate is momelotinib, a potent, selective, and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing a range of anemia benefits, including eliminating or reducing the need for frequent blood transfusions as well as spleen and constitutional symptom control. Momelotinib has been investigated in two completed Phase 3 clinical trials for the treatment of myelofibrosis. The product was acquired by Sierra Oncology from Gilead.

The company is also advancing two other products, SRA737 and SRA141. SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). Chk1 is a key regulator of cell cycle progression and the DDR (DNA Damage Response) damage response. Targeted inhibition of Chk1 by SRA737 may be synthetically lethal to cancer cells with elevated intrinsic replication stress and have utility as a monotherapy in a range of tumor indications.

SRA737 is being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer, one study as a monotherapy and the other study as a combination therapy with subtherapeutic, low dose gemcitabine. Sierra is also conducting pre-clinical research evaluating SRA737 in combination with other DDR-targeted agents, including poly ADP ribose polymerase (PARP) inhibitors, as well as with immuno-oncology therapeutics.

SRA141 on the other hand, is a potent, selective, and orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). It is a key regulator of DNA replication and is involved in the DDR network. An Investigational New Drug (IND) application is being prepared for submission in order to begin clinical trials.

Timeline

Patents

Further Resources

Title
Author
Link
Type
Date

Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit

Sierra Oncology

Web

Xconomy: Sierra Oncology Acquires Gilead's Stalled Myelofibrosis Drug

Web

News

Title
Author
Date
Publisher
Description
Nick Paul
August 5, 2021
FierceBiotech
AstraZeneca has offloaded its BRD4 BET inhibitor AZD5153 to Sierra Oncology. Sierra plans to start a phase 2 trial testing the drug in combination with the JAK inhibitor it picked up from Gilead in 2018.
Sierra Oncology
June 11, 2021
www.prnewswire.com:443
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,...
BioSpace
June 3, 2021
BioSpace
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced Georgia Erbez and Christy Oliger have joined the Company's Board of Directors.
Sierra Oncology
May 21, 2021
www.prnewswire.com:443
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,...
Sierra Oncology
May 7, 2021
www.prnewswire.com:443
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.